AXIM Biotechnologies (AXIM Biotechnologies) FCF Margin % : -2,018.87% (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is AXIM Biotechnologies FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. AXIM Biotechnologies's Free Cash Flow for the three months ended in Mar. 2024 was $-1.07 Mil. AXIM Biotechnologies's Revenue for the three months ended in Mar. 2024 was $0.05 Mil. Therefore, AXIM Biotechnologies's FCF Margin % for the quarter that ended in Mar. 2024 was -2,018.87%.

As of today, AXIM Biotechnologies's current FCF Yield % is -63.11%.

The historical rank and industry rank for AXIM Biotechnologies's FCF Margin % or its related term are showing as below:

AXIM' s FCF Margin % Range Over the Past 10 Years
Min: -22811.11 Med: -3175.51 Max: -2277.91
Current: -2277.91

During the past 13 years, the highest FCF Margin % of AXIM Biotechnologies was -2277.91%. The lowest was -22811.11%. And the median was -3175.51%.

AXIM's FCF Margin % is ranked worse than
83.17% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs AXIM: -2277.91

AXIM Biotechnologies FCF Margin % Historical Data

The historical data trend for AXIM Biotechnologies's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AXIM Biotechnologies FCF Margin % Chart

AXIM Biotechnologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-4,228.33

-22,811.11

-2,577.50

AXIM Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-2,028.57	-6,440.00	-2,650.00	153.85	-2,018.87

Competitive Comparison of AXIM Biotechnologies's FCF Margin %

For the Biotechnology subindustry, AXIM Biotechnologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AXIM Biotechnologies's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's FCF Margin % distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's FCF Margin % falls into.

AXIM Biotechnologies FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

AXIM Biotechnologies's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1.031	/	0.04
	=	-2,577.50 %

AXIM Biotechnologies's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-1.07	/	0.053
	=	-2,018.87 %

AXIM Biotechnologies FCF Margin % Related Terms

Thank you for viewing the detailed overview of AXIM Biotechnologies's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AXIM Biotechnologies (AXIM Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AXIM Biotechnologies Inc (OTCPK:AXIM) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6191 Cornerstone Court, E, Suite 114, San Diego, CA, USA, 92121

Website

https://www.aximbiotech.com

Axim Biotechnologies Inc is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, it owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications.

Executives

Kurt Phinney	officer: Chief Operating Officer	6914 MAGELLAN WAY, SARASOTA FL 34243
Peter O'rourke	director	C/O NORTHVIEW ACQUISITION CORP., 207 WEST 25TH STREET, 9TH FLOOR, NEW YORK NY 10001
Catalina Valencia	10 percent owner	6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Glycodots, Llc	10 percent owner	6191 CORNERSTONE COURT, E, SUITE 114, SAN DIEGO CA 92121
Juniper & Ivy Corp	10 percent owner	5201 MEMORIAL DRIVE, SUITE 616, HOUSTON TX 77007
Huemoeller John Walter Ii	director	305 SAN ANSELMO AVENUE, SUITE 300, SAN ANSELMO CA 94960
Blake Schroeder	director	5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert L Cunningham	director	5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Timothy Richard Scott	director	5 ROCKERFELLER PLACE, 20TH FLOOR, SUITE 83, NEW YORK NY 10111
Robert Malasek	officer: CFO	PO BOX 235472, ENCINITAS CA 92023
Lekhram Changoer	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Medical Marijuana, Inc.	10 percent owner	12255 CROSTHWAITE CIRCLE, POWAY CA 92064
Van Damme Philip A	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
Foundation Sanammad	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022
George Anastassov	10 percent owner	18 EAST 50TH STREET, 5TH FLOOR, NEW YORK NY 10022